文档介绍：洛铂临床研究进展
潘良平李林
四川省南充市中心医院西药剂科 637000
摘要:目的探讨洛铂临床研究进展情况。方法利用洛铂上市以来公开发表的文献,作一简要分析。结果 LBP单药或联合用药均对食管癌显示出较好的疗效,安全耐受性好以LBP为基础的联合化疗方案在胃肠癌中的疗效和以DDP、L-OHP为基础的方案无显著性差异。
结论洛铂作为新一代铂类抗肿瘤药物,虽然洛铂具有抗癌谱较广,与顺铂比较,无完全交叉耐药,且治疗指数较高,肾毒性和胃肠道不良反应较低,与其它化疗药物相配合呈现协同效应,使用方便等特点,但是它毕竟是一个新药,其疗效、安全性均需要大样本的进一步临床验证。
关键词:洛铂,铂类抗癌药物,临床I期试验,临床II期试验,II期后临床应用情况。
Summary
Objective. Discussing progress of clinical study of Lobaplatin.
Methods. Performing a brief analysis based on literatures which were published after Lobaplatin was introduced to the market.
Results. Lobaplatin as a single agent or bination with other agents has shown good effects on treatment of esophageal cancer. It’s safety and tolerability are evaluated to be good. Combined chemotherapy based on Lobaplatin has similar effects on esophageal pared with those based on DDP or L-OHP. It is also very convenient to bined with other chemotherapy drugs to show synergy effects. After all it is a new drug more clinical samples will be needed to evaluate its efficacy and safety.
Conclusions. As a new generation of platinum anticancer drugs, Lobaplatin
has a broad anticancer spectrum, no cross resistance with Cisplatin, high effects, low toxicity to kidneys and low side effects to intestines and stomach.
Key words. Lobaplatin, Platinum anticancer drugs, Clinical trial Phase I, Clinical trial Phase II, Clinical application after ph